Pfizer Inc

NYSE: PFE
$28.46
-$0.40 (-1.4%)
Closing Price on October 29, 2024

PFE Articles

With prescription drug spending breaking new records almost every year now, people like to blame Big Pharma and use it as the industry punching bag.
Sangamo Therapeutics saw its shares skyrocket early on Thursday after a critical business update.
The April 28 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mostly downward.
Pfizer reported mixed first-quarter financial results before the markets opened on Tuesday.
24/7 Wall St. has put together a preview of the Dow Jones Industrial Average companies scheduled to report their quarterly results this week.
24/7 Wall St. has put together a preview of Apple, Facebook, Pfizer and some of the other top companies reporting their latest results in the coming week.
The April 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
The March 31 short interest data have been compared with the previous figures, and short interest decreased in most of these selected pharmaceutical stocks.
Apple, DuPont, Goldman Sachs, and Pfizer led the DJIA to a lower close on Tuesday.
The March 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks was mixed.
With the major markets retreating from all-time highs, it began to look like the Trump rally was spent. Judging by the most shorted stocks traded on the New York Stock Exchange, overall short sellers...
24/7 Wall St. has taken a look at a few companies within the health care sector that might have seen a reaction from the health care vote in Congress, or lack thereof.
Goldman Sachs, DuPont, Boeing, and Pfizer weighed on the Dow Jones Industrial Average Friday.
DuPont, Chevron, Merck, and Pfizer sink the DJIA on Thursday.
The February 28 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.